Trinity Biotech plc's next confirmed earnings release is scheduled for December 10, 2026.
| Earnings Date | 12/10/2026 |
As of June 30, 2025, Trinity Biotech plc has 372.64M shares outstanding.
| Shares Outstanding | 372.64M |
As of June 30, 2025, Trinity Biotech plc maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.05 |
| Quick Ratio | 0.41 |
| Debt / Equity | -227.22 |
These figures cover the twelve months ended June 30, 2025.
| Employee Count | 390.50 |
Over the twelve months ended June 30, 2025, Trinity Biotech plc recorded 419,000.00 in income tax expense.
| Income Tax | 419,000.00 |
As of the close on November 16, 2026, Trinity Biotech plc's stock has declined approximately 79.61% over the past 52 weeks. The 50-day moving average sits at 6.85, while the 200-day moving average is 14.40.
| 52-Week Price Change | -79.61% |
| 50-Day Moving Average | 6.85 |
| 200-Day Moving Average | 14.40 |
As of June 30, 2025, Trinity Biotech plc holds 1.55M in cash and equivalents against 112.56M in total debt, resulting in a net debt position of 98.16M. Total book value stands at -49.54M, with working capital of 1.48M providing operational flexibility.
| Cash & Cash Equivalents | 1.55M |
| Total Debt | 112.56M |
| Net Debt | 98.16M |
| Equity (Book Value) | -49.54M |
| Book Value Per Share | -0.13 |
| Working Capital | 1.48M |
These figures cover the twelve months ended June 30, 2025.
| Capital Expenditures | -8.60M |
Trinity Biotech plc's most recent stock split took place on July 24, 2026 with a 30:1 split ratio.
| Last Split Date | 7/24/2026 |
| Split Ratio | 30:1 |
Already premium?